Participants will be enrolled in this study primarily to complete the 11-day AME portion of the study; participants who are receiving benefit from SNDX-5613 may remain on study until progressive disease (PD) or unacceptable toxicity.
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 ([14C])-SNDX-5613 in participants with acute leukemia.